Follistim Shortage: What Providers and Prescribers Need to Know in 2026

For reproductive endocrinologists, OB/GYNs, and urologists managing fertility patients, medication availability is a critical factor in treatment planning. Follistim AQ (Follitropin Beta) — one of the most widely prescribed recombinant FSH products in the US — continues to present access challenges for patients in 2026. This briefing covers the current landscape and actionable strategies for your practice.

Current Status: Not Officially in Shortage, but Practically Constrained

As of Q1 2026, Follistim AQ is not listed on the FDA Drug Shortage Database or the ASHP drug shortage list. However, the clinical reality is that patients frequently report difficulty filling Follistim prescriptions, particularly through retail pharmacy channels.

This disconnect between official shortage status and patient experience reflects the structural characteristics of the Follistim supply chain rather than a single acute shortage event.

Timeline: How We Got Here

Understanding the supply context requires looking at several converging factors:

• 2020-2022: COVID-19 pandemic disrupted pharmaceutical supply chains broadly, including specialty biologics. Many patients deferred fertility treatment, creating pent-up demand.
• 2023-2024: Post-pandemic fertility treatment volumes surged. The American Society for Reproductive Medicine (ASRM) reported year-over-year increases in IVF cycle starts. Demand for gonadotropins including Follistim increased accordingly.
• 2024-2025: Organon, which was spun off from Merck in 2021, continued as the sole US manufacturer. No biosimilar FSH products entered the US market. Intermittent supply constraints were reported at individual specialty pharmacies.
• 2026: Supply remains adequate at the national level but unevenly distributed. Patients without established specialty pharmacy relationships face the greatest access barriers.

Prescribing Implications

The current supply landscape has several implications for clinical practice:

Protocol Flexibility

Consider maintaining protocol flexibility that allows switching between Follistim (Follitropin Beta) and Gonal-F (Follitropin Alfa) based on availability. Published literature supports comparable outcomes between the two products, and most IVF protocols can accommodate either without significant dose adjustments.

Early Prescription Submission

Encourage your practice to submit Follistim prescriptions to specialty pharmacies at least 7-10 days before the patient's anticipated cycle start. This provides buffer time for insurance verification, prior authorization processing, and any stock-related delays.

Patient Communication

Proactively discuss medication availability with patients during their treatment planning consultation. Setting expectations early — including the possibility of switching to an equivalent gonadotropin — reduces patient anxiety and prevents last-minute scrambles that can delay cycle starts.

Availability Picture: Where Patients Can Find Follistim

The distribution landscape for Follistim is heavily concentrated in specialty pharmacy channels:

• Specialty fertility pharmacies (Freedom Fertility, Avella, MDR, Village Fertility, Alto) maintain the most consistent stock
• Hospital outpatient pharmacies affiliated with academic fertility centers often carry Follistim
• Retail chain pharmacies (CVS, Walgreens, Rite Aid) generally do not stock Follistim and require special ordering with variable turnaround
• Mail-order specialty pharmacies can ship temperature-controlled Follistim to patients nationwide

For practices looking for a tool to help patients locate stock, Medfinder for Providers offers real-time pharmacy availability data that can be integrated into your patient communication workflow.

Cost and Access Considerations

Cost remains a significant barrier for Follistim access:

• Cash pricing: $800-$2,600 per cartridge depending on strength; $5,000-$10,000+ per IVF cycle for Follistim alone
• Insurance coverage: Varies significantly by state and plan. 20+ states have fertility insurance mandates, but coverage depth varies. Many plans require prior authorization and may mandate use of specific specialty pharmacies.
• Manufacturer support: Organon's ReUnite Rx program offers 25-75% savings for eligible cash-paying patients on Follistim AQ, Ganirelix, and Pregnyl. Refer patients to reuniterx.com or info@reuniterx.com.
• Additional resources: Livestrong Fertility (for oncofertility patients), Baby Quest Foundation, and other nonprofit grants can help offset costs for qualifying patients.

For a comprehensive breakdown of patient savings options, see our post on how to save money on Follistim, which you can share with your patients.

Tools and Resources for Your Practice

Medfinder for Providers

Medfinder helps providers and patients check real-time pharmacy stock for fertility medications including Follistim AQ. Rather than having your staff call multiple pharmacies, direct patients to Medfinder to find available stock in their area. The platform covers specialty and retail pharmacies nationwide.

Alternative Medication Quick Reference

When Follistim is unavailable, the following alternatives are supported by clinical evidence:

• Gonal-F (Follitropin Alfa): Most direct substitute. Recombinant FSH with comparable efficacy and safety profile. Available in pre-filled pens (300, 450, 900 IU) and vials.
• Menopur (Menotropins): Purified urinary-derived FSH + LH. Useful as a combination or standalone in protocols requiring LH supplementation. 75 IU per vial.
• Pergoveris (Follitropin Alfa + Lutropin Alfa): Combination recombinant FSH/LH for patients with severe gonadotropin deficiency.

For detailed comparisons, review our patient-facing article on alternatives to Follistim.

Practical Workflow for Your Staff

For a step-by-step guide on integrating availability checking and patient support into your clinical workflow, see our companion post: How to Help Your Patients Find Follistim in Stock: A Provider's Guide.

Looking Ahead

Several developments may improve the Follistim access landscape in the coming years:

• Biosimilar pipeline: While no FSH biosimilar has been approved in the US, the international availability of biosimilar follitropin products suggests FDA submissions may be forthcoming.
• State mandate expansion: Additional states are considering or advancing fertility insurance mandate legislation, which could increase covered access to Follistim and reduce the burden on cash-paying patients.
• Specialty pharmacy growth: The fertility pharmacy market continues to expand, with more players offering competitive pricing and improved access for patients across the country.

Final Thoughts

Follistim AQ remains a cornerstone of fertility treatment protocols. While supply challenges persist, they are manageable with proactive planning, protocol flexibility, and the right tools. Equipping your practice and your patients with up-to-date information on availability, alternatives, and cost-saving resources will help keep treatment on track.

For more provider resources, visit Medfinder for Providers. For additional provider guidance on helping patients save on this medication, see our post on how to help patients save money on Follistim.